Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 140 av 140 resultater
Tid
Selskap
Tittel
Sektor
Kategori
17 Feb 2022
07:35 CET
VALBIOTIS
Valbiotis annonce avoir reçu les autorisations de lancer les deux études cliniques de Phase II/III INSIGHT et INSIGHT 2, dernière étape du développement de TOTUM•854 pour la réduction de la pression artérielle
20103010 Biotechnology
Products and services
17 Feb 2022
07:35 CET
VALBIOTIS
Valbiotis Announces Approval to Launch the Two Phase II/III INSIGHT and INSIGHT 2 Clinical Studies, the Last Step in the Development of TOTUM•854 For the Reduction of Blood Pressure
20103010 Biotechnology
Products and services
28 Jan 2022
17:40 CET
VALBIOTIS
Valbiotis : Bilan semestriel du contrat de liquidité
20103010 Biotechnology
Other subject
06 Jan 2022
07:35 CET
VALBIOTIS
Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure
20103010 Biotechnology
Other subject
06 Jan 2022
07:35 CET
VALBIOTIS
Valbiotis - Accélération du calendrier clinique sur des indications majeures : des résultats attendus en 2022 dans le prédiabète, l’hypercholestérolémie et la pression artérielle
20103010 Biotechnology
Other subject
01 Dec 2021
07:35 CET
VALBIOTIS
Valbiotis annonce avoir soumis aux autorités compétentes les trois protocoles cliniques pour TOTUM•854 indiqué dans la réduction de la pression artérielle et présente son plan de développement clinique complet
20103010 Biotechnology
Other subject
01 Dec 2021
07:35 CET
VALBIOTIS
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
20103010 Biotechnology
Other subject
15 Nov 2021
07:35 CET
VALBIOTIS
Valbiotis annonce des résultats précliniques positifs de TOTUM•070 contre l’hypercholestérolémie, sélectionnés et présentés au congrès annuel de l’American Heart Association (AHA)
20103010 Biotechnology
Other subject
15 Nov 2021
07:35 CET
VALBIOTIS
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
20103010 Biotechnology
Other subject
30 Sep 2021
07:38 CEST
VALBIOTIS
Rapport financier semestriel 2021
20103010 Biotechnology
Corporate life
30 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis Reviews Its Activities and Publishes Its Financial Report for the First Half of 2021
20103010 Biotechnology
Other subject
30 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis fait le point sur ses activités et publie son rapport financier pour le premier semestre 2021
20103010 Biotechnology
Other subject
24 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER
20103010 Biotechnology
Other subject
24 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis consolide son développement de solutions de santé naturelles innovantes en intégrant l'exploration de micro-algues produites en Nouvelle-Calédonie, au travers d'un accord exclusif avec l’ADECAL-Technopole et l’IFREMER
20103010 Biotechnology
Other subject
09 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis publie sa Lettre aux actionnaires 2021
20103010 Biotechnology
Other subject
09 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis Releases its Letter to Shareholders for 2021
20103010 Biotechnology
Other subject
06 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
20103010 Biotechnology
Other subject
06 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis annonce la fin du recrutement de l’étude clinique de Phase II HEART conduite avec TOTUM•070 contre l’hypercholestérolémie, facteur de risque des maladies cardiovasculaires
20103010 Biotechnology
Other subject
28 Jul 2021
07:45 CEST
VALBIOTIS
Document d'enregistrement universel
20103010 Biotechnology
Corporate life
27 Jul 2021
21:39 CEST
VALBIOTIS
Valbiotis : Mise à disposition du Document d’enregistrement universel
20103010 Biotechnology
Other subject
22 Jul 2021
17:40 CEST
VALBIOTIS
Valbiotis : Bilan semestriel du contrat de liquidité
20103010 Biotechnology
Other subject
28 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis annonce la réalisation de l’étude clinique de mode d’action sur TOTUM•63 par l’INAF1 de l’Université Laval à Québec, en partenariat avec Nestlé Health Science
20103010 Biotechnology
New
28 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
20103010 Biotechnology
New
07 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer
20103010 Biotechnology
Other subject
07 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis nomme Sébastien BESSY, expert international en Consumer Healthcare, Directeur des Opérations Marketing et Commerciales
20103010 Biotechnology
Other subject
03 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action
20103010 Biotechnology
Other subject
03 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis annonce la publication des premiers articles scientifiques sur TOTUM•63 dans trois revues internationales, décrivant son mécanisme d’action multicible
20103010 Biotechnology
Other subject
26 May 2021
17:52 CEST
VALBIOTIS
Valbiotis Granted a €1.25 Million Innovation Support Loan by Bpifrance
20103010 Biotechnology
Other subject
26 May 2021
17:52 CEST
VALBIOTIS
Valbiotis bénéficie d’un soutien à l’innovation de Bpifrance de 1,25 million d’euros
20103010 Biotechnology
Other subject
19 May 2021
17:40 CEST
VALBIOTIS
Valbiotis obtient le brevet pour sa substance active TOTUM•63 en Chine, un vaste marché potentiel pour la prévention du diabète de type 2 et des maladies métaboliques
20103010 Biotechnology
Corporate life
19 May 2021
17:40 CEST
VALBIOTIS
Valbiotis Obtains Patent for Its Active Substance TOTUM•63 in China, a Large Potential Market for the Prevention of Type 2 Diabetes and Metabolic Diseases
20103010 Biotechnology
Corporate life
12 May 2021
17:40 CEST
VALBIOTIS
Valbiotis' Combined General Meeting on May 27, 2021 Will Exceptionally Be Held Behind Closed Doors
20103010 Biotechnology
General meeting / Board Meeting
12 May 2021
17:40 CEST
VALBIOTIS
L’Assemblée Générale Mixte du 27 mai 2021 de Valbiotis se tiendra exceptionnellement à huis clos
20103010 Biotechnology
General meeting / Board Meeting
28 Oct 2020
07:43 CET
VALBIOTIS
Rapport financier semestriel 2020
20103010 Biotechnology
Legal
26 Oct 2018
15:38 CEST
VALBIOTIS
Rapport financier semestriel 30 juin 2018
Biotechnology
-
26 Oct 2018
15:37 CEST
VALBIOTIS
Rapport financier annuel 31 décembre 2017
Biotechnology
Corporate life
24 Jul 2018
15:51 CEST
VALBIOTIS
Bilan semestriel du contrat de liquidité confié à la société Portzamparc
Biotechnology
-
31 Jan 2018
18:14 CET
VALBIOTIS
Bilan semestriel du contrat de liquidité VALBIOTIS confié à la société PORTZAMPARC
Biotechnology
-
29 Sep 2017
07:36 CEST
VALBIOTIS
Rapport financier semestriel au 30 juin 2017
Biotechnology
Income
06 Jul 2017
19:05 CEST
VALBIOTIS
Bilan semestriel du contrat de liquidité VALBIOTIS confié à la société PORTZAMPARC
Biotechnology
-
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva